P16.31 Improving timely hiv results in key populations: rapid test antibody evaluation for hiv diagnosis in guatemala, 2012–2013. (13th September 2015)

• Record Type: Journal Article
• Authors: Arana Flora, E; Castillo-Signor, L; Marchorro, P; Girón, V; Lopez, A; Escobar, C; Vargas, C; Mendizabal-Burastero, R; Morales-Miranda, S
• Is Part Of: Sexually transmitted infections. Volume 91(2015)Supplement 2
• Page Start: A222
• Page End: A223
• Publication Date: 2015-09-13
• Subjects: Sexually transmitted diseases -- Periodicals; HIV infections -- Periodicals; 616.951005
• DOI: 10.1136/sextrans-2015-052270.578
• Languages: English
• ISSNs: 1368-4973

Abstract

Abstract : Introduction: Guatemala has a concentrated HIV epidemic among key populations; in 2003, the first rapid test validation in Central America was performed. A national HIV testing algorithm with a rapid test and a second test using an enzyme immunoassay (EIA) was developed (average turnaround time of 2 weeks). Given the changes in the market since 2003, we present results of a second rapid test validation to update the Guatemalan algorithm. Methods: Validation was performed in 2012–2013, evaluating a total of 10 rapid tests in two phases: 1) with serum, HIV-negative samples were obtained from blood banks, and positive samples from HIV care units; 2) with whole blood, negative samples were obtained from antenatal care services and positive samples from HIV care units. We tested 452 serum samples [244 HIV+, 208 HIV-] and 432 whole blood samples (10 HIV positive, 422 HIV negative) using two EIA (Roche ELECSYS HIV Combi and Abbott AXSYM HIV Ag/Ab Combo). Discordant results were evaluated with HIV-1 Western Blot. For fourth generation rapid tests, only antibody was evaluated. Data was analysed using OpenEpi. Results: Six HIV rapid tests were included for both phases. All tests (except Double Check Gold) reported sensitivity higher than 99% and specificity higher than 95%. Determine HIV 1/2 and HIV Ag/Ab reported the highest results for sensitivity (100%). Hexagon HIV (100%) and Accu-Tell (99.5%) reported the highest results for specificity. All rapid tests that also included HIV-2 detection, showed cross-reactivity, ranging from 37% of HIV cases for Anarapid HIV 1/2/O Tri-line to 15% for Rapid HIV 1/2/O Tri-Line. Conclusion: Our results show that Determine HIV½ and HIV Ag/Ab should be recommended as a screening test while Hexagon HIV and Accu-Tell should be recommended as second test. Rapid test validation provides valuable information for on-site confirmation of reactive results improving diagnosis turnaround time. Disclosure of interest statement: We declare that we have no conflicts of interest.